Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA

Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad

This strategic investment strengthens Cohance's integrated oligonucleotide platform

Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad

Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

ekincare launches elva.AI to resolve 80% of employee healthcare queries

Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men